IMB-102 / IMBiologics, Huadong Medicine - LARVOL DELTA

Huadong Medicine introduces two autoimmune products... [Google translation] (bydrug.pharmcube.com) - "Zhongmei Huadong obtained exclusive rights to develop, register, manufacture, and commercialize IMB-101 and IMB-102, two of IMB's globally innovative autoimmune products, in 37 Asian countries, including China (excluding Japan, South Korea, and North Korea). Zhongmei Huadong will pay IMB a US$6 million upfront payment, a US$2 million technology transfer milestone payment, up to US$307.5 million in development, registration, and sales milestone payments, and tiered double-digit royalties on net sales."

Licensing / partnership • Immunology

Y-Biologics, IMBiologics partner again to develop antibody drugs for autoimmune diseases (Korea Biomedical Review) - "Y-Biologics and IMBiologics announced Wednesday that they have signed a collaboration agreement to jointly research and develop new antibody drug candidates for autoimmune diseases....The two companies have co-developed IMB-101 (OXTIMA, a bispecific antibody targeting OX40L/TNF-α) and IMB-102 (a monoclonal antibody targeting OX40L) for autoimmune diseases with HK inno.N and transferred the technology to Navigator Medicine in the U.S. for $944.7 million (1.37 trillion won) in June 2024 and to China’s Huadong Medicine for $315.5 million in August."

Licensing / partnership • Immunology